BOC-Linagliptin Synthesis via Ring-Closing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for synthesizing Linagliptin face challenges in removing impurities, particularly on an industrial scale, due to the protecting group used in the synthesis process.
Innovation Solution
A new process involving different synthetic routes for the preparation of BOC-Linagliptin through intermediates, utilizing ring-closing reactions in various solvents and catalysts to form the quinazoline part of Linagliptin on the xanthine scaffold, allowing for the efficient formation of Quinazolinyl-xanthine and subsequent conversion to BOC-Linagliptin.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If existing synthesis methods with protecting groups are used, then Linagliptin can be synthesized, but impurity formation increases and becomes difficult to remove
Solution Approach 1:
The invention extracts and eliminates the protecting group (BOC) from the synthesis pathway by using a direct ring-closing method that forms the quinazoline structure without requiring protective group chemistry. This removes the source of impurities associated with protecting group installation and removal steps.
Solution Approach 2:
The synthesis is segmented into two main stages: first forming the quinazolinyl-xanthine core structure through ring-closing, then subsequently introducing the BOC-protected piperidine moiety. This segmentation allows each transformation to be optimized independently, reducing cross-contamination and impurity formation.
2Ease of manufacture
If conventional synthesis routes are used, then Linagliptin production is achieved, but the process complexity increases due to multiple protection/deprotection steps
Solution Approach 1:
The invention performs preliminary action by pre-forming the quinazolinyl-xanthine core structure before introducing the piperidine substituent. This preliminary ring-closing creates a stable intermediate that simplifies subsequent functionalization steps and eliminates the need for protecting group manipulations on the xanthine core.
Solution Approach 2:
The conventional approach installs protecting groups first and then builds the molecule; this invention inverts the sequence by first building the core structure without protecting groups, then adding substituents. This inversion simplifies the overall synthetic route by eliminating protecting group chemistry.
3Productivity
If existing methods are scaled up for industrial production, then output increases, but impurity removal becomes more difficult and costly
Solution Approach 1:
The invention converts the potential harm of direct ring-closing reactions (which could generate byproducts) into a benefit by selecting specific reaction conditions and reagents that导向 high selectivity. The ring-closing step uses controlled conditions that minimize side reactions, making the process more suitable for scale-up despite the direct nature of the transformation.
Data Source
AI summary
This invention relates to novel processes for the synthesis of Linagliptin, the pharmaceutically active ingredient, and the key intermediate thereof, BOC-Linagliptin. (I) The processes are performed via new intermediate compounds of Formula (5) and Formula (3).